Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert J. Perez, currently Executive Vice President and Chief Operating Officer (COO), has been named President and COO, and Michael Tomsicek, currently Vice President of Corporate Finance, has been named Senior Vice President and Deputy Chief Financial Officer. In addition, Thomas Rollins has been appointed Senior Vice President of Program and Portfolio Management. “As we recently articulated in our Building Blocks of Growth strategic goals, attracting, retaining and developing top talent are critical to growing and expanding our business on a global basis, and I am delighted today to announce these senior appointments,” said Michael Bonney, Chief Executive Officer. “Rob and Mike are exceptional leaders who have made significant contributions to our recent operational and financial success, and we’re pleased to have them take on added responsibilities. We’re also delighted that Tom will join our senior Cubist leadership team, adding strengths across all phases of our product development process.” In Mr. Perez’s role as President and COO, he will oversee all global commercial, manufacturing, business development, and information technology functions. In this capacity, he will have responsibility for overseeing Cubist's international business expansion. Mr. Perez has been EVP and COO since 2007. He joined Cubist in 2003 as Senior Vice President of Cubist’s sales and marketing team and then served as SVP of Commercial Operations from 2004 to 2007. Prior to joining Cubist, he spent eight years at Biogen Idec, where he most recently served as Vice President of the company’s CNS Business Unit. From 1987 to 1995, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals, including serving as Regional Business Director. In Mr. Tomsicek’s new role as SVP and Deputy CFO, he will oversee all financial planning and analysis, technical accounting, controllership, treasury, tax, commercial financial services, and strategic sourcing activities, reporting to David McGirr, Chief Financial Officer. Mr. Tomsicek joined Cubist in 2010. Prior to Cubist, he spent eight years at General Electric Healthcare, initially as global operations Finance Manager for its Monitoring business, and then as CFO of its diagnostic ultrasound business and CFO of its global ultrasound product group. Previously, Mr. Tomsicek served in a variety of financial and channel management roles at Motorola.
Mr. Rollins joins Cubist from Sunovion Pharmaceuticals, Inc., a subsidiary of Dainippon Sumitomo Pharmaceuticals Inc., where he has been SVP of Program Management and R&D Planning since 2009. He spent 15 years at Sepracor Inc. most notably serving as Vice President of Development Operations from 2001-2005 and Senior Vice President of Product Development from 2005-2009. Prior to Sepracor, he held numerous senior research and project positions at Merck Research Laboratories. As SVP of Program and Portfolio Management at Cubist, Mr. Rollins will be responsible for maximizing the value of Cubist products and product candidates on a global basis. He will report to Steven Gilman, Cubist’s Executive Vice President, Research & Development and Chief Scientific Officer.About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com.